A Deimmunized Bispecific Ligand-Directed Toxin That Shows an Impressive Anti–Pancreatic Cancer Effect in a Systemic Nude Mouse Orthotopic Model

Renal Excretion of Recombinant Immunotoxins ContainingPseudomonasExotoxin

(2011) Roberta Traini et al.   BIOCONJUGATE CHEMISTRY

Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases

(2010) D. A. Vallera et al.   MOLECULAR CANCER THERAPEUTICS

A New Drug Delivery Method of Bispecific Ligand-Directed Toxins, Which Reduces Toxicity and Promotes Efficacy in a Model of Orthotopic Pancreatic Cancer

(2010) Seunguk Oh et al.   PANCREAS

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics☆

(2009) Satoshi Nagata et al.   ADVANCED DRUG DELIVERY REVIEWS

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity

(2009) B J Stish et al.   BRITISH JOURNAL OF CANCER

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

(2009) S. Oh et al.   CLINICAL CANCER RESEARCH

Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model

(2008) D. A. Vallera et al.   GUT

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

(2008) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA